Amryt Pharma shareholders agree to acquisition by Chiesi
Maksim Labkouski
- Amryt Pharma (NASDAQ:AMYT) shareholders have approved the company's acquisition by Chiesi Farmaceutici.
- The deal is expected to close in Q2.
- Although the waiting period under the Hart-Scott-Rodino Antitrust Act has ended, the transaction is subject to other approvals and closing conditions.
- Chiesi paid ~$1.25B in upfront consideration plus contingent value rights representing an additional ~$225M of potential consideration.